The Clinical Cooperation Unit Nuclear Medicine works on the planning and monitoring of therapies, the pharmacokinetic modeling of PET measurements, the identification of tumor-affine peptides, new endoradiotherapeutic approaches, alternating biopanning strategies and combinatorial therapies consisting of endoradiotherapy, chemotherapy, immunotherapy and radiotherapy as well as the development of new treatments for non-iodine-storing thyroid carcinomas.
The KKE Nuclear Medicine deals with the planning and monitoring of chemotherapy or radiotherapy, the pharmacokinetic modeling of dynamic PET measurements, the identification of new peptides with high affinity to tumors, the establishment of new endoradiotherapeutic approaches based on peptides and antibodies, the development of new alternating biopanning strategies with phage and ribosome display and recombinant proteins, membrane fractions and cells, the development of combinatorial therapy approaches with endoradiotherapy and chemotherapy, immunotherapy and radiotherapy and the development of new therapies for non-iodine-storing thyroid carcinoma.
Sachpekidis C, Enqvist O, Ulén J, Kopp-Schneider A, Pan L, Jauch A, Hajiyianni M, John L, Weinhold N, Sauer S, Goldschmidt H, Edenbrandt L, Dimitrakopoulou-Strauss A
2023 - Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1158-1167
Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, Sachpekidis C, Humbert O, Gheysens O, Glaudemans AWJM, Weber W, Wahl RL, Scott AM, Pandit-Taskar N, Aide N.
2021 - Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4472-4482
